Cover Story
ClinicalTrials & Tribulations
By Wenora Johnson, Danielle Ripley-Burgess, Heather Hampel, Folasade (Fola) P. May, Anjee Davis and Richard M. Goldberg
Technological advances are transforming our understanding of cancer, accelerating the evolution of new treatment approaches. In the past decades, researchers deploying new techniques for analyzing DNA have extended our knowledge of inherited genetic abnormalities that can predispose a person to develop colorectal and other cancers.
In Brief
Funding Opportunities
Clinical Roundup
Trending Stories
- What will Trump’s return to the White House mean for oncology?
“Our work just got a lot more difficult.” - Trump 2016: A look back at the 45th president’s impact on oncology
- A study measures the long-term downside of prostate cancer screening
A paper in JAMA Oncology focuses on the harms of overscreening, overdiagnosis, and overtreatment - At an uncertain time for cancer research and public health, Wayne Frederick steps in as interim CEO at ACS
- Long-term risks from prostate cancer treatment detailed in new report
- GRAIL’s woes raise questions about the prospects of MCDs and standards for their evaluation